Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: a Subgroup Analysis from Three International Cohorts
Sharmin Sifat, Univ Rennes, CHU Rennes, Inserm, CIC (Centre d’Investigation Clinique de Rennes),Andersen Johanna Balslev,Horakova Dana,Havrdova Eva Kubala,Alroughani Raed,Izquierdo Guillermo,Ozakbas Serkan, University of Catania,Onofrj Marco, Università di Bologna,Terzi Murat,Grammond Pierre,Grand’Maison Francois,Yamout Bassem,Prat Alexandre,Girard Marc,Duquette Pierre,Boz Cavit,Trojano Maria,Royal Brisbane and Women’s Hospital,Slee Mark, Hunter New England Health,Turkoglu Recai,Sola Patrizia,Ferraro Diana, Parma University Hospital,Prevost Julie,Maimone Davide,The Alfred Hospital,Monash University,Van Wijmeersch Bart,Csepany Tunde,Spitaleri Daniele,Vucic Steve, EUGENE DEVIC EDMUS Foundation Against Multiple Sclerosis, State-Approved Foundation, Université de Lorraine, APEMAC,Edan Gilles,Ciron Jonathan, CHU de Bordeaux, CIC Bordeaux CIC140,De Sèze Jérôme, Centre de Ressources et de Compétences SEP,Zephir Hélène, University of Montpellier (MUSE),Defer Gilles,Lebrun-Frénay Christine,Moreau Thibault,Berger Eric, Université Clermont Auvergne, Inserm, Neuro-Dol,Pelletier Jean, Department of Neurology, AP-HP, Saint-Antoine Hospital,Gout Olivier, Institut de Génomique Fonctionnelle, UMR52 INSERM , Univ. Montpellier,Heinzlef Olivier,Al-Khedr Abullatif,Bourre Bertrand,Casez Olivier,Cabre Philippe,Montcuquet Alexis,Wahab Abir,Camdessanché Jean-Philippe,Maurousset Aude,Patry Ivania,Hankiewicz Karolina,Pottier Corinne,Maubeuge Nicolas,Labeyrie Céline,Nifle Chantal, CRTI-Inserm U106, Koch-Henriksen Niels,Sellebjerg Finn Thorup,Soerensen Per Soelberg,Pfleger Claudia Christina,Rasmussen Peter Vestergaard,Jensen Michael Broksgaard, University of Copenhagen,Bramow Stephan,Mathiesen Henrik Kahr,Schreiber Karen Ingrid,Magyari Melinda, Université Claude Bernard Lyon, Faculté de médecine Lyon Est,Royal Melbourne Hospital CNS drugs（2021）
Key words
subgroup analysis,comparative treatment efficiency,natalizumab vs fingolimod,registry data,longitudinal studyPage Break
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper